Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial [0.03%]
米塔扎平作为一种多巴胺受体抑制剂预防重度致吐性化疗后延迟期恶心呕吐的二次诱导研究：一项开放标签、随机、多中心III期临床试验
Jun Cao,Quchang Ouyang,Shusen Wang et al.
Jun Cao et al.
Background We examined the efficacy of mirtazapine in preventing delayed nausea and vomiting following highly emetogenic chemotherapy (HEC). Patients and methods Patients who had experienced delayed emesis and would be subsequently schedule...
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies [0.03%]
加拿大癌症试验组的一项 Ib 期研究：在晚期不可治愈的实体瘤患者中联合使用或依次序使用德瓦鲁单抗（PD-L1 抑制剂）和曲美木单抗（CTLA-4 抑制剂）的效果
J Nehra,P A Bradbury,P M Ellis et al.
J Nehra et al.
Background The IND.226 study was a phase Ib study to determine the recommended phase II dose of durvalumab + tremelimumab in combination with standard platinum-doublet chemotherapy. Sequential administration of multiple agents increases tot...
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia [0.03%]
RO6839921（MDM2拮抗剂）治疗急性髓系白血病患者的Ⅰ期临床研究
Geoffrey L Uy,Sarit Assouline,Anne-Marie Young et al.
Geoffrey L Uy et al.
In acute myeloid leukemia (AML), TP53 mutations and dysregulation of wild-type p53 is common and supports an MDM2 antagonist as a therapy. RO6839921 is an inactive pegylated prodrug of the oral MDM2 antagonist idasanutlin (active principle ...
Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells [0.03%]
代谢组学谱分析评估新型雄激素受体拮抗剂普卡那肽治疗前列腺癌细胞的效果
Feng Qu,Yue Gu,Qizhi Wang et al.
Feng Qu et al.
Proxalutamide is a newly developed androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (PCa) that has entered phase III clinical trials. In the present study, we intended to elucidate the antitumor ef...
The structure and regulation of the E3 ubiquitin ligase HUWE1 and its biological functions in cancer [0.03%]
E3泛素连接酶HUWE1的结构、调控及其在癌症中的生物学功能
Xiaofeng Gong,Danyu Du,Yanran Deng et al.
Xiaofeng Gong et al.
E3 ligases are a class of critical enzymes that can catalyse the transfer of ubiquitin (Ub) from an E2 enzyme to the substrate and are essential to cellular processes. The E3 ligase HUWE1 (also known as ARF-BP1, HECTH9, HSPC272, Ib772, LASU...
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma [0.03%]
盐酸耐维明酯治疗肾上腺皮质癌的I期临床研究：一种新型特异性靶向肾上腺固醇O-酰基转移酶1（SOAT1）抑制剂
David C Smith,Matthias Kroiss,Electron Kebebew et al.
David C Smith et al.
Background Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with very limited treatment options. Nevanimibe HCl (formerly ATR-101), a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, has been shown in n...
A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma [0.03%]
帕博西尼联合卡铂治疗不可手术的复发或转移性头颈部鳞癌的多中心Ⅱ期临床研究
Paul L Swiecicki,Greg Durm,Emily Bellile et al.
Paul L Swiecicki et al.
Background Palbociclib is a selective inhibitor of CDK4/6 approved in metastatic breast cancer as well as evidence of activity in malignancies with CDK4-amplifications. Extensive preclinical evidence has demonstrated synergy of CDK4/6 inhib...
Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia [0.03%]
低剂量伊布替尼序贯治疗B细胞前体淋巴细胞白血病1例报告
Satoko Oka,Kazuo Ono,Masaharu Nohgawa
Satoko Oka
B cell prolymphocytic leukemia (B-PLL) is a rare and aggressive disease that is associated with poor survival. Although initially asymptomatic patients do not require therapy, most patients will progress and inevitably require treatment. Mo...
KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth [0.03%]
KRCA-0008对ALK阳性间变性大细胞淋巴瘤生长的抑制作用
Jungjoong Hwang,Insuk Song,Kwangho Lee et al.
Jungjoong Hwang et al.
Anaplastic lymphoma kinase (ALK), which belongs to the insulin receptor tyrosine kinase superfamily, plays an important role in nervous system development. Due to chromosomal translocations, point mutations, and gene amplification, constitu...
Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients [0.03%]
脂质体包裹的丝裂霉素C脂质前药的药代动力学及其在转移性结直肠癌患者中的临床相关性研究
Alberto A Gabizon,Esther Tahover,Talia Golan et al.
Alberto A Gabizon et al.
Background Pegylated liposomal (PL) mitomycin-c lipidic prodrug MLP) may be a useful agent in patients with metastatic colo-rectal carcinoma (CRC). We report here on the pharmacokinetics and clinical observations in a phase 1A/B study with ...